Compare BL & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BL | ZYME |
|---|---|---|
| Founded | 2001 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2016 | 2022 |
| Metric | BL | ZYME |
|---|---|---|
| Price | $28.88 | $22.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 11 |
| Target Price | ★ $56.62 | $38.90 |
| AVG Volume (30 Days) | ★ 980.2K | 531.8K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $177,031,000.00 | $105,965,000.00 |
| Revenue This Year | $12.62 | $183.10 |
| Revenue Next Year | $10.90 | N/A |
| P/E Ratio | $211.08 | ★ N/A |
| Revenue Growth | ★ 43.78 | 38.87 |
| 52 Week Low | $24.70 | $11.86 |
| 52 Week High | $59.57 | $29.75 |
| Indicator | BL | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 50.08 | 36.89 |
| Support Level | $28.09 | $22.20 |
| Resistance Level | $31.14 | $23.66 |
| Average True Range (ATR) | 1.36 | 0.92 |
| MACD | -0.11 | -0.30 |
| Stochastic Oscillator | 45.77 | 1.07 |
BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their critical processes, including financial close & consolidation, intercompany accounting, and invoice-to-cash. The majority of the revenue of the company is earned in the United States.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.